news

liu yilin, a reporter from eastday.com, reported on september 22: today, dr. schwann, chairman of the board of directors of roche group, attended the 36th international business leaders advisory meeting of the mayor of shanghai (hereinafter referred to as iblac). as the chairman of iblac, dr. schwann exchanged views and held discussions with all parties, and offered suggestions for the development of shanghai.

"shanghai has an excellent business environment, strong economic strength and profound cultural heritage, and has been accumulating strength for long-term development, which provides unprecedented development opportunities for multinational companies including roche. china is a strategic market for roche, and we are full of confidence in our long-term development in the chinese market," said dr. schwan.

dr. schwann, chairman of the board of directors of roche group and chairman of iblac (photo provided by the interviewee, the same below)

as an old friend of iblac, roche has participated in the meeting for more than 20 consecutive years, and dr. schwan has also attended the meeting as scheduled for 15 consecutive years, contributing his foresight to the development of shanghai. focusing on the sub-topic of "continuously expanding open science and technology cooperation", dr. schwan combined international cutting-edge experience to guide member companies to conduct in-depth discussions to promote shanghai's higher level of openness, cooperation and innovation.

as one of the three key industries in shanghai, biomedicine is flourishing as never before. shanghai will be at the forefront of global medical research, with a thriving biotechnology industry, top hospitals and research institutions, while preventive healthcare will become part of daily life.

dr. schwann, chairman of the board of directors of roche group and chairman of iblac, delivered a speech at the 36th shanghai mayor's international entrepreneurs advisory meeting

this year marks the 30th anniversary of roche pharmaceuticals in china. roche has announced a longer-term development plan and a clearer vision. it will continue to accelerate the pace of introducing innovative products into china and continue to strengthen the end-to-end complete pharmaceutical value chain to help realize the grand blueprint of "healthy china 2030" as soon as possible.

as of now, roche has 28 products in china, covering 8 major therapeutic areas. in 1994, as the first multinational company to settle in zhangjiang, pudong, roche took the lead in building and continuously upgrading and improving the entire industry chain in china. as one of the earliest foreign pharmaceutical companies to establish a research and development center in china, roche's research and development has been rooted in china for 20 years and has continued to increase investment. roche china innovation center covers new drug research and development in the fields of immunology, tumors and metabolic diseases, and continuously develops innovative drugs for patients.